The abstract is read at the publisher; the summary is JClub's.
Obinutuzumab β plus standard therapy increased SRI-4 responses at week 12 in Chinese adults with active systemic lupus erythematosus, from 34% to 52%.
- Why it matters: B cells are implicated in systemic lupus erythematosus, yet effective and safe targeted options for active disease remain needed.
- What they did: In a multicentre randomized double-blind phase 2 trial in China, 123 patients received intravenous obinutuzumab β 1000 mg or placebo on specified days while continuing background therapy; the primary endpoint was SRI-4 at week 12.
- The result: At week 12, 32/61 (52%) versus 21/62 (34%) achieved SRI-4 (adjusted risk difference 19 percentage points, 95% CI 3–36; p=0·022), with serious adverse events in 20% vs 23% over 52 weeks.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.